• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

Lay-offs start December 1st - You heard it here first!

Quote
Gale Seely MRI 800-979-8701 1115 gseely@mrportland.com
Bill Baracani 877-454-6600 bill@harbeckassociates.com
Lori Harbeck Harbeck & Assoc 309-454-2456 lori@harbeckassociates.com
Kathy MSA 800-818-1761 www.msajobs.com, rx@msajobs.com
Justin Endres Bowdoin Group 800-239-3141 jendres@bowdoingroup.com
Brett Rice Same Same 5205 Same
David Melville Same 800-239-3141 dmelville@bowdoingroup.com
Stephen Thorley 800-239-3141 781-235-5632 sthorley@bowdoingroup.com
Keith Graham HCR Network 410-239-6464 Keith.graham@hcrnetwork.com
Arlene Gleason 800-506-4728 103 arlene@patlicata.com
Stacy Rupert Same 119
Ryan Carfley 919-460-9595 113 919-460-0642
Troy Radmer Med Recruiters 877-897-5627 troyr@medrecruiters.com
Rob Schraf MRI 614-252-6200 322 rob.schraf@princetonsearch.com
Dan Kerr 412-492-0300 dankerr@telerama.com
Execu search 412-374-9904 exec12@earthlink.net
George Kafes Spherion 919-425-2727 919-941-0073 georgekafes@spherion.com
Eric White MRI 800-976-1972 103 434-591-1139 eric@pharmarecruiting.com
Al Clark MRI of WI 920-722-9700 920-915-3949 C al@erjmri.com
Robin Schreiber HCR Network 262-241-3333 1 robin.schreiber@hcrnetwork.com
Thomas Bergquist HCR Network 412-261-2244 412-261-3577 tom.bergquist@hcrnetwork.com
Simon McCune HCR Network 810-227-7055 102 248-388-2597C simon.mccune@hcrnetwork.com
Joe Alabarces Career Adv 954-340-6670 954-340-6675 jra@wagrp.com
Kevin Wright Marcus & Ass 914-941-5356 116 914-941-8064 kwright@marcusassoc.com
Amy Hoffman Self hoff451@aol.com
James Henly Talent Tactics 610-862-0529 jhenly@talentactics.com
Rick Snowden SMR Group 877-789-2001 jason@smrgroupltd.com
Larry Wisniewski Alexander Michaels Assoc. 800-767-9988 Fax 800-249-5683 larry@alexandermichaels.com
Michelle Fiorillo Leslie Gaber & Ass 800-409-1123 732-409-6632 michelle@lesliegaber.com
Christine Poltorak SFG International 908-272-9600 19 cp@sfginternational.com
Karen Demay 781-894-5614 karendemay@comcast.net
Alexey Dvortcksak Genentech 503-235-6536 503-475-8555 alexeyd@gene.com
Tony Bishop Systems 1 Res 866-797-8361 864-627-0013 tbishop@system1.net
Bill Bissonette 865-691-2700 wbissonette@aol.com
Kris Beyer Med Search USA 714-964-8874 kris@medsearchusa.com
Howard Shotel 610-941-0800 25 h.shotel@ecarecruiters.com
Janet Meyer HCR Network 972-661-0055 209 janet.meyer@hcrnetwork.com
Ryan Harris Bales Group 904-398-9080 213 904-422-6040 rharris@balescompany.com
Bill Russell Russell Group 908-709-1188 bill.russell@russellgrp.com
Eric Heger MRI of Napa 707-257-4427 e.heger@sbcglobal.net
Tom Halligan Career Consultants 412-655-9700 412-655-7149 tomh@ccicareer.com
Roddy Delaney MRI of Pittsburgh 724-935-1774 12 412-736-4314 C roddy@mripittsburghwest.com
Ruthann Berry CST 908-522-0069 202 ruthann@cstllc.com
Barbara O'Rourke Atlantic Mgmt Res 908-791-9000 borourke@amrjobs.com
John Campo Campo Group 270-685-2820 jcampo@campogroup.com
Allison Miller Carter Mackay 516-616-7700 203 apl1123 amiller@cartermackay.com
Chris Ross Carter Mackay 617-689-0029 508-450-5409 C cross@cartermackay.com
Michael Scott Carter Mackay 919-380-1200 212 mscott@cartermackay.com
Frank MRI Indy 877-733-9644 frank@mriz.net
Lisa Manley Joppa Medical Rec 978-499-0547 lmanley@joppamedicalrecruiting.com
Mike Johnson 973-540-8900 mike@corporate-search.com
Jackie Beverly RMA Sales 404-325-2189 205 Jackie_beverly@rmasales.com
Russ Mountain RMA Sales 404-325-2189 www.rmasales.com
Bennett Adam Concord Search Grp 610-940-0550 106 267-255-9337C adam@concordsearch.com
Alicia Fillippini Concord Search Grp 610-940-0550 105 215-817-7693 alicia@concordsearch.com

Ed Rosenstein (800) 624-2495 rosensteinassoc@aol.com
Jeff Spicer (574) 233-9353 jsp000@aol.com
Mike Zulliani (615) 771-9594
Tom Godfrey (800) 364-8574 x2 webmaster@searchmark.com
Larry Orbeck (516) 616-7700 x207
Mike Peskosky (704) 846-5204 primesearch@carolinarr.com
Scott Tutton (336) 882-4507 tuttsearch@aol.com
Heather Matthews and Mindy Burns (916) 635-4800 hmatthews@system1.net
Linda Bailey (305) 365-7890 (786) 586-2817 Cell linda@medicalrecruiters.com
Misty Doonis w/ L. Bailey (410) 821-5941 (410) 458-9858 Cell mdoonis@medicalrecruiters.com
Bales Co. Ryan Harris VM (904) 398-9080 x213 (904) 422-6040 Cell rharris@balescompany.com
Steve Dill & Assoc. (623) 551-0261
Kathleen Ormond (215) 943-6896 prosourcing@comcast.net
Mgt. Recruiters. Katy Brady (847) 604-9000 x16 katy@mrilf.com
Mullins Grp. Matt Kaufman (561) 243-8883 mkaufman@mullinsgroup.com
Vann Morris grp. Dann Vann (405) 348-4921 (405) 474-7982 Cell dvann@career-searches.com
Mark Canastrea (310) 265-9996 mark@apex-careers.com
Diane Courtney (704) 489-1424 eagleseye33@bellsouth.net
Rose Hays (800) 875-6188 x111 rhays@mrirecruiter.net
Jean Killacky (650) 685-1000 x104 (415) 305-0685 Cell jean@skutzman.com
Rass Bagley (336) 626-4009 bagley@asheboro.com
Steve Paster (504) 486-7080
Ken (720) 904-1777 ken@prime-core.com
 




























Yes it is gay and 2,030 viewers agree 100% with you. Please do not read the very first post, because your little tiny brain does not have the capacity to comprehend any of it.
 




Anonymous said:
Yes it is gay and 2,030 viewers agree 100% with you. Please do not read the very first post, because your little tiny brain does not have the capacity to comprehend any of it.
Click to expand...

Oh I did read it you r*****. Still blown away by the pride you have in publishing your profoundly stupid ideas on cafe pharma, then citing the number views to prove that it's actually a credible claim that TZD's are going to be pulled in November.

With a title like "you're gonna get laid off", of course people are going to look. Doesn't make it credible. It just proves that you get a kick out of trying to stir up crap and scare people. Loser.
 












I really don't want to have to wait until December 2nd to call the original poster a douchebag for posting such a dumb topic....but I will.




Fuck it



OP...you are a douchebag! See you on Dec 2nd!!
 








The plot thickens !!!

What a fucking dirty ass company - with so many secrets to hide and so little time left.

This is why Eli Lilly stopped co promoting this product, to keep clear of the bombshell :(

If you want to believe that all this shit is made-up by some girl who wants to make people "scared", then you may want to start looking up the proof source(s) for yourself. They are all listed on the very first post of this thread, with the exception to the one below which was found just recently.

http://www.bmj.com/cgi/eletters/331/7520/836#119507

-----------------------------------------------------------------------

5 years ago today: Pioglitazone data - when all 30 authors are wrong
On 8 October 2002 Nick Freemantle (University of Birmingham) reported in the BMJ (BMJ 2005;331:836-838) that clinical trial findings involving the drug Pioglitazone (the PROactive trial) had been misrepresented and that the conclusions were unsafe.

A response by a reader (Dr James Penston) was pertinent and bears on the responsibilities of authorship. His letter was entitled "When all thirty authors are wrong".

Penston writes: "Perhaps this was simply an innocent error. But it is hard to believe that none of the thirty authors – including 27 professors – were aware that it would be misleading to interpret the data as showing that pioglitazone reduced macrovascular events. Given that 28 of the 30 authors had financial links with the pharmaceutical industry and that the study was funded by Takeda and Eli Lilly, it would have been prudent to avoid at all cost the charge that this manipulation of data stemmed from a conflict of interest."
 




Anonymous said:
The plot thickens !!!

What a fucking dirty ass company - with so many secrets to hide and so little time left.

This is why Eli Lilly stopped co promoting this product, to keep clear of the bombshell :(

If you want to believe that all this shit is made-up by some girl who wants to make people "scared", then you may want to start looking up the proof source(s) for yourself. They are all listed on the very first post of this thread, with the exception to the one below which was found just recently.

http://www.bmj.com/cgi/eletters/331/7520/836#119507

-----------------------------------------------------------------------

5 years ago today: Pioglitazone data - when all 30 authors are wrong
On 8 October 2002 Nick Freemantle (University of Birmingham) reported in the BMJ (BMJ 2005;331:836-838) that clinical trial findings involving the drug Pioglitazone (the PROactive trial) had been misrepresented and that the conclusions were unsafe.

A response by a reader (Dr James Penston) was pertinent and bears on the responsibilities of authorship. His letter was entitled "When all thirty authors are wrong".

Penston writes: "Perhaps this was simply an innocent error. But it is hard to believe that none of the thirty authors – including 27 professors – were aware that it would be misleading to interpret the data as showing that pioglitazone reduced macrovascular events. Given that 28 of the 30 authors had financial links with the pharmaceutical industry and that the study was funded by Takeda and Eli Lilly, it would have been prudent to avoid at all cost the charge that this manipulation of data stemmed from a conflict of interest."
Click to expand...

All of the posts related to the site above conclude what most reps are saying in the field, don't use pio in symptomatic CHF patients and Actos has not been shown to sig. increase total macrovascular events vs. standard of care. Secondary benefits are rarely mentioned in the study overview. As far as the funding of PROactive, who do these guys think would ever fund such a costly study but the company that produces the drug. Get a clue chicken little.
 




The FDA seems to have had ample evidence about the risks associated with Actos and Avandia. In 2006, FDA drug safety advisor Dr. Rosemary Johann-Liang urged the agency to add a black box warning to Actos and Avandia because of serious cardiovascular risks. Instead of heeding her warning, however, the agency reprimanded Johann-Liang and did nothing to adequately inform consumers about the possible risks associated with Actos and Avandia.
 




Anonymous said:
The FDA seems to have had ample evidence about the risks associated with Actos and Avandia. In 2006, FDA drug safety advisor Dr. Rosemary Johann-Liang urged the agency to add a black box warning to Actos and Avandia because of serious cardiovascular risks. Instead of heeding her warning, however, the agency reprimanded Johann-Liang and did nothing to adequately inform consumers about the possible risks associated with Actos and Avandia.
Click to expand...

Is this made up bull crap or does anyone out there really know if this was indeed a true account of what happened involving this Doctor and the FDA?

Sounds kind of ....
 








You are all fucked, you talked your shit how Actos was so safe and had no issues. Besides having the same cardiovascular issues as Avandia you guys were saying how different you were from Avandia. Guess what your right... You cause bladder cancer. Actos suppresses p-par alpha which ,over supresses the immune system and guess what increase of bladder cancer. When this comes out I am going to tell every doctor had bad your drug is you fucking dirty ass reps. Get your resumes ready. HA HA !!!!!!
 




Anonymous said:
You are all fucked, you talked your shit how Actos was so safe and had no issues. Besides having the same cardiovascular issues as Avandia you guys were saying how different you were from Avandia. Guess what your right... You cause bladder cancer. Actos suppresses p-par alpha which ,over supresses the immune system and guess what increase of bladder cancer. When this comes out I am going to tell every doctor had bad your drug is you fucking dirty ass reps. Get your resumes ready. HA HA !!!!!!
Click to expand...

I'm sure you will...I hope you frame it as eloquently as your post...this confirms why avandia is losing market share...I'm sure you make GSK proud.
 




Top Bottom
Back
Quote